natgillin/translations-raw huggingface dataset:
The background incidence of intussusception in infants less than one year of age in these countries ranged from 33 to 101 per 100,000 infants per year.
Osnovna pojavnost invaginacije v teh državah se je pri dojenčkih, mlajših od enega leta, gibala med 33 in 101 na 100.000 dojenčkov na leto.
The backing foil should be peeled off and the capsule can be removed.
Odlepite zaščitno folijo in vzemite ven kapsulo.
The backing layer is transparent to translucent and labelled with “R5” (Rivastigmine 3M Health Care Ltd.
Krovna plast je prozorna do prosojna in in označena z oznako “R5” (Rivastigmin 3M Health Care Ltd.
The backing layer is transparent to translucent, labelled with “R10” in a repeated pattern.
Krovna plast je prozorna do prosojna in označena z oznako “R10” v ponavljajočem se vzorcu.
The backing layer is transparent to translucent, labelled with “R5” in a repeated pattern.
Krovna plast je prozorna do prosojna in označena z oznako “R5” v ponavljajočem se vzorcu.
The backing layer of Neupro contains aluminium.
Oporna plast obliža zdravila Neupro vsebuje aluminij.
The bacteria that cause the disease also make a toxin (poison) that can damage the heart, kidneys and nerves.
Bakterije, ki povzročajo to bolezen, proizvajajo tudi toksin (strup), ki lahko poškoduje srce, ledvice in živce.
The bacteria were isolated between 2001 and 2007 from clinical cases in Belgium, France, Germany, Hungary, Italy, Poland, Sweden and UK.
Bakterije so v obdobju od 2001 do 2007 izolirali iz kliničnih primerov v Belgiji, Nemčiji, Madžarski, Poljski, Švedski in Združenem Kraljevstvu.
The bactericidal responses against the NHBA antigen were also high in infants vaccinated at the 2, 4, 6-month schedule, but this antigen appeared to be less immunogenic at the 2, 3, 4-month schedule.
Baktericidni odzivi proti antigenu NHBA so bili veliki tudi pri dojenčkih, cepljenih v shemi 2, 4, 6 mesecev, vendar izgleda, da je ta antigen manj imunogen v shemi 2, 3, 4 mesecev.
The bacterium strain included in Equilis StrepE has had some genes removed, so that it grows less well inside the horse’s body and is less likely to cause disease.
Sevu bakterije, ki ga vsebuje zdravilo Equilis StrepE, so bili odstranjeni nekateri geni, zato v telesu konja slabše raste in obstaja manjša verjetnost, da bi povzročil bolezen.
The bag containing the reconstituted and diluted VFEND should be used immediately, but if necessary may be stored for up to a total of 24 hours at 2°C - 8°C (in a refrigerator) or at room temperature. (Please refer to the end of this leaflet for further information).
Vrečko z rekonstituiranim in redčenim zdravilom VFEND je treba uporabiti takoj, če pa je treba, jo lahko shranimo pri temperaturi med 2 °C in 8 °C (v hladilniku) ali pri sobni temperaturi za največ 24 ur (dodatne informacije najdete na koncu tega navodila).
The bag contains a volume of 10-100 mL of frozen dispersion at a concentration of 5-20 x 106 cells/mL
Vreča vsebuje 10 do 100 ml zamrznjene disperzije v koncentraciji 5 do 20 x 106 celic/ml.
The bag contains a volume of 10-100 mL of frozen dispersion at a concentration of 5-20 x 106 cells/mL
Zdravilo Zalmoxis vsebuje 10 do 100 ml zamrznjene disperzije v koncentraciji 5 do 20 x 106 celic/ml.
The bag does not require any specific storage conditions.
Za shranjevanje vrečke niso potrebna posebna navodila.
The bag injection site should be wiped with an alcohol pad and the suspension in the syringe should be injected into the original bag containing the remaining 50 ml of sodium chloride 9 mg/ml (0.9%) solution for injection (Figure 4).
Mesto, kjer boste prebodli vrečko, morate obrisati z alkoholno blazinico, suspenzijo v brizgi pa injicirajte v originalno vrečko, ki vsebuje preostalih 50 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje (slika 4).
The bag of vaccine should be gently swirled frequently during vaccination to guarantee that the vaccine suspension remains homogenous and that the correct vaccine virus titre is administered (e.g. during long vaccination sessions).
Vrečko s cepivom je treba med cepljenjem večkrat narahlo obračati, da je zagotovljeno, da suspenzija za injiciranje ostane homogena in da je dan pravilni titer vakcinalnega virusa (npr. med dolgimi postopki cepljenja)
The bag should be gently inverted to mix the solution in order to avoid foaming.
Vrečko je potrebno nežno obračati in zmešati raztopino tako, da se izognemo penjenju.
The bag should be inverted gently to mix the solution.
Vrečko previdno obračajte, da boste raztopino premešali.
The bag should be removed from the insulated polyurethane container and inspected for leaks, external damage, foreign particulate matter, or clumps/clots.
Vrečko vzemite iz izoliranega poliuretanskega vsebnika in preglejte, ali pušča, ima vidne poškodbe, prisotne tujke ali grudice/strdke.
The bag should be removed from the liquid nitrogen, put in a double bag container and thawed in a pre-warmed water bath at 37 °C. Upon full cell dispersion thawing, the bag is dried, disinfected and ready to be infused at a rate prescribed by the physician.
Vrečo je treba vzeti iz tekočega dušika, položiti v vsebnik z dvojno vrečo in odtajati v vodni kopeli pri 37 °C. Po popolnem odtajanju disperzije celic je vreča po osušitvi in razkužitvi pripravljena na infundiranje s hitrostjo, ki jo predpiše zdravnik.
The baits are distributed by land or by air within the framework of vaccination campaigns against rabies.
Vabe se polagajo ročno ali iz zraka v okviru akcije cepljenja proti steklini.
The baits are successively packed in boxes of :
Vabe so zaporedoma pakirane v zloženke po:
The BALLR1 study, also evaluating the effects of iNO in preterm neonates, but initiating iNO at 7 days and in a dose of 20 ppm, found a significant increase in neonates alive without BPD at gestational week 36, 121 (45 % vs.
Študija BALLR1, ki je prav tako ocenjevala učinke iNO pri nedonošenčkih, vendar se je iNO uvedel po 7 dnevih v odmerku 20 ppm, je ugotovila pomembno povečano število živih novorojenčkov brez BPD v 36. in 121. gestacijskem tednu (45 % v primerjavi s 95 (35,4 %) p < 0,028).
The banana flavoured granules for oral suspension is a white to off-white powder that may contain yellow or beige to tan particles in a single-use sachet.
Zrnca za peroralno suspenzijo z okusom banane so bel do sivo bel prašek, ki lahko vsebuje rumene ali bež do rumeno rjave delce, v vrečici za enkratno uporabo.
The bar-code label marked “30-minute-value” must be used for this sample.
Za ta vzorec je treba uporabiti črtno kodo z napisom "30-minutna vrednost".
The bar-code labels marked “30-minute-value” must be used for these samples.
Za ta vzorca je treba uporabiti črtno kodo z napisom "30-minutna vrednost".
The Barn, Manor Farm, Church Lane Chilcompton, Somerset BA3 4 HP
The Barn, Manor Farm, Church Lane
The basal metabolic requirement is 40% to 60% of the total daily requirement.
Osnovna presnovna potreba predstavlja od 40 do 60 % celotne dnevne potrebe.
The baseline characteristics and duration of fondaparinux treatment were comparable in both UFH groups.
Izhodiščne značilnosti in trajanje zdravljenja s fondaparinuksom so bili v obeh skupinah UFH primerljivi.
The baseline characteristics for this population included: median age 63 years (42% age 65 or older); 61% male; 72% White and 21% Asian and 34% and 66% with an ECOG performance status 0 and 1, respectively.
Izhodiščne značilnosti te populacije so bile: mediana starost 63 let (42 % starih 65 let ali več), 61 % moških, 72 % belcev in 21 % Azijcev ter 34 % s stanjem zmogljivosti 0 in 66 % s stanjem zmogljivosti 1 po ECOG.
The baseline demographic and disease characteristics were similar between the axitinib and sorafenib groups with regard to age, gender, race, Eastern Cooperative Oncology Group (ECOG) performance status, geographic region, and prior treatment.
Na začetku študije so bile demografske in na bolezen nanašajoče se značilnosti v obeh skupinah (z aksitinibom in sorafenibom) podobne, kar se tiče starosti, spola, rase, stanja zmogljivosti, ocenjenega po Eastern Cooperative Oncology Group (ECOG), zemljepisnega področja in predhodnega zdravljenja.
The baseline demographic were comparable between the lenalidomide arm and control arm.
Izhodiščne demografske značilnosti so bile primerljive med skupino z lenalidomidom in kontrolno skupino.
the batch number of the medicine, and the injected volume, flow rate, the number and location of infusion sites.
erijo zdravila in injicirani volumen, hitrost infundiranja in število mest infundiranja ter njihov položaj.
the batch number of the medicine, and the injected volume, flow rate, the number and location of injection sites.
številko serije zdravila in injicirano prostornino, hitrost pretoka, število in lokacije mest injiciranja.
The BCIRG 006 study was designed to investigate combining Herceptin treatment with docetaxel either following AC chemotherapy or in combination with docetaxel and carboplatin in patients with HER2 positive EBC following surgery.
Preskušanje BCIRG 006 je bilo zasnovano za proučevanje kombinacije zdravljenja z zdravilom Herceptin in docetakselom, bodisi po kemoterapiji z doksorubicinom in ciklofosfamidom (kemoterapiji AC) bodisi v kombinaciji z docetakselom in karboplatinom pri bolnikih z zgodnjo obliko HER2-pozitivnega raka dojk po operaciji.
The BCRP inhibition could result in increased exposure of medicinal products such as imatinib, lapatinib, methotrexate, pitavastatin, rosuvastatin, sulfasalazine, and topotecan (see section 5.2).
Zaviranje proteina BCRP lahko povzroči povečano izpostavljenost zdravilom, kot so imatinib, lapatinib, metotreksat, pitavastatin, rosuvastatin, sulfasalazin in topotekan (glejte poglavje 5.2).
The Bemfola and GnRH agonist are then both given until your follicles develop as desired.
Nato se dajeta zdravilo Bemfola in agonist GnRH do želenega razvoja foliklov.
The beneficial effect of enoxaparin on the primary efficacy endpoint was a constant in all key subgroups distinguished on the basis of age, sex, location of myocardial infarction, diabetes, a history of prior myocardial infarction, the type of fibrinolytic and time to initiation of treatment with the IMP.
Ugodni učinek enoksaparina na primarni izid učinkovitosti je bil stalen v vseh ključnih podskupinah, ki so se razlikovale glede na starost, spol, mesto miokardnega infarkta, sladkorno bolezen, anamnezo predhodnega miokardnega infarkta, vrsto uporabljenega fibrinolitika in čas do začetka zdravljenja s preiskovanim zdravilom.
The beneficial effect of enoxaparin on the primary endpoint observed during the first 30 days was held over a 12-month observation period.
Ugodni učinek enoksaparina na primarni izid učinkovitosti v prvih 30 dneh zdravljenja se v 12-mesečnem opazovalnem obdobju ni spremenil.
The beneficial effect of enoxaparin on the primary endpoint was consistent across key subgroups including age, gender, infarct location, history of diabetes, history of prior myocardial infarction, fibrinolytic administered and time to treatment with study medicinal product.
Ugodni učinek enoksaparina na primarni izid učinkovitosti je bil dosleden v vseh ključnih podskupinah, ki so se razlikovale glede na starost, spol, mesto miokardnega infarkta, anamnezo sladkorne bolezni, anamnezo predhodnega miokardnega infarkta, vrsto uporabljenega fibrinolitika in čas do začetka zdravljenja s študijskim zdravilom.
The beneficial effect of vedolizumab on clinical response, remission and mucosal healing was observed both in patients with no prior TNF antagonist exposure as well as in those who had failed prior TNF antagonist therapy.
Koristen učinek vedolizumaba na klinični odziv, remisijo in celjenje sluznice so opazili tako pri bolnikih, ki se predhodno še niso zdravili z zaviralcem TNFα, kot tudi pri bolnikih, ki se na predhodno zdravljenje z zaviralcem TNFα niso odzvali.
The beneficial effect of Zenapax prophylaxis upon the incidence of acute rejection after renal transplantation was not associated with adverse clinical sequelae, including the development of Post- Transplant Lymphoproliferative Disease (PTLD), at 3 years posttransplant.
Dobrodejen učinek profilakse z Zenapaxom 3 leta po presaditvi na osnovi incidence akutne zavrnitve po presaditvi ledvic ni bil povezan z neželenimi kliničnimi posledicami, vključno z razvojem posttransplantacijske limfoproliferativne bolezni (PTLD – Post-Transplant Lymphoproliferative Disease).
The benefit of amprenavir boosted with ritonavir has not been demonstrated in PI naïve patients.
Pri bolnikih, ki še niso bili zdravljeni z zaviralcem proteaz, korist okrepitve učinka amprenavirja z ritonavirjem ni bila dokazana.
The benefit of MabThera maintenance treatment was confirmed in all subgroups analysed, regardless of induction regimen (CHOP or R-CHOP) or quality of response to induction treatment (CR or PR) (table 7).
Korist vzdrževalnega zdravljenja z zdravilom MabThera so potrdili v vseh analiziranih podskupinah, ne glede na indukcijsko shemo (CHOP ali R-CHOP) ali vrsto odgovora na indukcijsko zdravljenje (CR ali PR) (preglednica 7).
The benefit of the product in the AMD patient population who have occult subfoveal CNV with evidence of recent or ongoing disease progression has not been demonstrated consistently.
V skupini bolnikov z okultno subfovealno CNV z znaki nedavnega ali prisotnega napredovanja bolezni koristnost zdravila Visudyne ni bila enotno dokazana.
The benefit of the vaccination of pigs with very high levels of maternally-derived antibodies, e.g. due to vaccination of their mothers, has not been demonstrated.
Korist cepljenja prašičev z zelo visokimi nivoji maternalnih protiteles, npr. zaradi cepljenja njihovih mater, ni bila prikazana.
The benefit of treatment with Zavesca for neurological manifestations in patients with Niemann-Pick type C disease should be evaluated on a regular basis, e.g. every 6 months; continuation of therapy should be re-appraised after at least 1 year of treatment with Zavesca, (see section 4.4).
Koristi zdravljenja z zdravilom Zavesca pri nevroloških manifestacijah pri bolnikih z Niemann- Pickovo boleznijo tipa C je treba redno preverjati, npr. vsakih 6 mesecev; za nadaljevanje terapije se je treba ponovno odločiti po vsaj 1-letnem zdravljenju z zdravilom Zavesca (glejte poglavje 4.4).
The benefit of treatment with Zavesca for neurological manifestations in patients with Niemann-Pick type C disease should be evaluated on a regular basis, e.g. every 6 months; continuation of therapy should be re-appraised after at least 1 year of treatment with Zavesca.
Koristi zdravljenja z zdravilom Zavesca pri nevroloških manifestacijah pri bolnikih z Niemann- Pickovo boleznijo tipa C je treba redno preverjati, npr. vsakih 6 mesecev; za nadaljevanje terapije se je treba ponovno odločiti po vsaj 1-letnem zdravljenju z zdravilom Zavesca.
The benefit to the patient of treatment with Zavesca should be evaluated on a regular basis (see section 4.4).
Koristi zdravljenja z zdravilom Zavesca je treba pri bolnikih redno preverjati (glejte poglavje 4.4).
The benefit was smaller when Cyramza was given on its own, but this could still be a therapeutic option when treatment with paclitaxel is not considered appropriate.
Koristi zdravila Cyramza so bile manjše, ko so ga dajali samostojno, vendar je tovrstna uporaba kljub temu lahko terapevtska možnost, kadar se oceni, da paklitaksel ni primeren.
The benefit was sustained after 3 years of follow-up.
Po treh letih spremljanja so bile koristi še vedno nespremenjene.
The benefit- risk balance may be found in module 6 of this EPAR.
Razmerje med koristmi in tveganji je v modulu 6 tega Evropskega javnega poročila o oceni zdravila (EPAR).
The benefit- risk balance may be found in module 6 of this EPAR.
Razmerje med koristmi in tveganji najdete v modulu 6 tega Evropskega javnega poročila o oceni zdravila (EPAR).
The benefit- risk balance may be found in the scientific discussion module of this EPAR.
Za razmerje med koristmi in tveganji glejte modul o znanstveni razpravi tega evropskega javnega poročila o oceni zdravila (EPAR).
The benefit-risk assessment in individual dogs should take into account the details in the product literature.
Ocena razmerja med koristjo in tveganjem za posameznega psa mora upoštevati podrobnosti v literaturi o zdravilu.
The benefit-risk balance may be found in module 6 of this EPAR.
Razmerje med koristmi in tveganji je mogoče najti v modulu 6 tega EPAR.
The benefit/risk assessment for the individual dog should take into account the details in the product literature.
Ocena razmerja med koristjo in tveganjem za posameznega psa mora upoštevati podrobnosti v literaturi o zdravilu.
The benefit/risk balance may be found in the scientific discussion module of this EPAR.
Razmerje med koristmi in tveganji je na voljo v modulu o znanstveni razpravi v tem evropskem javnem poročilu o oceni zdravila (EPAR).
The benefit/risk balance of bosentan has not been established in patients with WHO class I functional status of pulmonary arterial hypertension.
Pri bolnikih s funkcijskim stanjem pljučne arterijske hipertenzije razreda I po klasifikaciji Svetovne zdravstvene organizacije razmerja med koristjo in tveganjem za bosentan še niso ugotovili.
The benefit/risk ratio for TAC in patients with 4+ nodes was not defined fully at the interim analysis (see section 5.1).
Za uporabo pri starostnikih glede na analizo farmakokinetike na populaciji ni posebnih navodil.
The benefits and risks of Budesonide/Formoterol Teva Pharma B.V. are therefore taken to be the same as those of the reference medicine.
Koristi in tveganja zdravila Budesonide/Formoterol Teva Pharma B.V. so torej enaki kot pri referenčnemu zdravilu.
The benefits and risks of continued weekly Humira therapy should be carefully reconsidered in a patient with an inadequate response after the increase in dosing frequency (see section 5.1).
Koristi in tveganja nadaljevanja tedenskega zdravljenja z zdravilom Humira je treba ponovno natančno pretehtati pri bolniku z nezadostnim odzivom na zdravljenje po povečanju pogostnosti odmerjanja (glejte poglavje 5.1).
The benefits and risks should be considered before continuing treatment with dabrafenib in patients with a non-cutaneous malignancy that has a RAS mutation.
Pri bolnikih z nekožnim malignomom z mutacijo RAS je treba pred odločitvijo za nadaljevanje zdravljenja z dabrafenibom pretehtati koristi in tveganja takega zdravljenja.
The benefits of Caprelsa may be smaller for patients who do not have a mutation in a gene called the ‘rearranged during transfection’ (RET) gene or if this is not known, and this should be taken into account when deciding whether to start treatment.
Koristi zdravila Caprelsa so morda manjše za bolnike, ki nimajo mutacije gena, imenovanega gen RET ali „med transfekcijo prerazporejeni gen“, ali če to ni znano, kar je treba upoštevati ob odločanju za uvedbo zdravljenja.
The benefits of Cometriq may be smaller for patients whose cancer does not have a mutation in a gene called the ‘re-arranged during transfection’ (RET) gene, and this should be taken into account when deciding whether to start treatment.
Koristi zdravila so lahko manjše pri bolnikih, ki nimajo mutacije gena, imenovanega gen RET (re- arranged during transfection – prerazporejen med transfekcijo), kar je treba upoštevati pri odločanju o uvedbi zdravljenja.
The benefits of EndolucinBeta will largely depend on the medicine that it is used to radiolabel.
Koristi zdravila EndolucinBeta so precej odvisne od zdravila, ki je z njim radioaktivno označeno.
The benefits of Eperzan were studied in over 5,000 patients with type 2 diabetes in which Eperzan was compared with placebo (a dummy treatment) or with other diabetes medicines when used as an add- on to various combination treatments or when used alone.
Koristi zdravila Eperzan so proučevali pri več kot 5000 bolnikih s sladkorno boleznijo tipa 2, pri katerih so zdravilo Eperzan primerjali s placebom (zdravilom brez zdravilne učinkovine) ali z drugimi zdravili za zdravljenje sladkorne bolezni, kadar se zdravilo Eperzan uporablja kot dodatek k različnim kombiniranim zdravljenjem ali samostojno.
The benefits of Lumark will largely depend on the medicine that it is used to radiolabel.
Koristi zdravila Lumark so v veliki meri odvisne od zdravila, za radiooznačevanje katerega se uporabi.
The benefits of Lymphoseek were shown in two main studies in which 311 patients with breast or skin cancer had their lymph nodes first mapped with Lymphoseek and then with another method involving the use of a dye known as ‘vital blue dye’.
Koristi zdravila Lymphoseek so bile dokazane v dveh glavnih študijah, v katerih so 311 bolnikom z rakom dojke ali kožnim rakom mapirali bezgavke, in sicer najprej z zdravilom Lymphoseek, nato pa z drugo metodo, ki vključuje uporabo „vitalnega modrega barvila“.
The benefits of Nucala in severe eosinophilic asthma that is not well controlled by previous treatment have been shown in three main studies, in which it was compared with a placebo (dummy) injection.
Koristi zdravila Nucala pri težki eozinofilni astmi, ki ni dobro urejena s predhodnimi zdravili, so se izkazale v treh glavnih študijah, v katerih so zdravilo primerjali z injiciranjem placeba (zdravila brez zdravilne učinkovine).
The benefits of Ongentys in Parkinson’s disease were investigated in two main studies.
Koristi zdravila Ongentys pri Parkinsonovi bolezni so proučevali v dveh glavnih študijah.
The benefits of ongoing treatment should be regularly evaluated by your doctor against the risk of bleeding.
Zdravnik mora redno ocenjevati koristi zdravljenja zaradi tveganja za krvavite.
The benefits of Uptravi for PAH were shown in one main study involving 1,156 patients with PAH.
Koristi zdravila Uptravi pri PAH so pokazali v eni glavni študiji, v kateri je bilo vključenih 1 156 bolnikov s PAH.
The benefits of Zontivity were clearest in a group of 16,897 patients who had had a heart attack, but had no history of stroke or transient ischaemic attack (so-called ‘mini stroke’).
Koristi zdravila Zontivity so bile najbolj opazne v podskupini 16 897 bolnikov, ki so doživeli srčni infarkt, vendar v anamnezi niso imeli možganske kapi ali prehodne pretočne motnje (ali tranzitorne ishemične atake, tako imenovane „mini kapi“).
The Benepali pre-filled pen is for a subcutaneous injection.
Napolnjen injekcijski peresnik z zdravilom Benepali je za subkutano injiciranje.
The Benepali pre-filled syringe is for a subcutaneous injection.
Napolnjena injekcijska igla z zdravilom Benepali je za subkutano injiciranje.
The best dose to use in patients below 18 years of age is not known.
Najprimernejši odmerek za uporabo pri bolnikih, mlajših od 18 let, ni znan.
The best method of administration of the oral solution is directly into the bird’s mouth.
Najboljši način dajanja peroralne raztopine je neposredno v usta ptice.
The best overall SEGA response rate had increased to 57.7% (95% CI: 47.9, 67.0) at the final analysis.
Ob končni analizi se je delež bolnikov z najboljšim skupnim odzivom SEGA povečal na 57,7 % (95-odstotni IZ: 47,9, 67,0).
The best places for injections are where the skin is loose and soft, and away from joints, nerves, bones, for example the abdomen, arm, thigh or buttocks.
Najboljše mesto za injiciranje je predel, kjer je koža mlahava in mehka, ne v bližini sklepov, živcev in kosti, na primer trebuh, roka, stegno ali zadnjica.
The best places to give yourself an injection are: the front of your thighs, the front of your waist (abdomen), or the upper arm.
Najprimernejša mesta za injiciranje so: sprednji del stegen, sprednji del trebuha ali nadlakti.
The best places to inject are the front of your thighs, upper arms or the front of your waist (abdomen).
Najprimernejša mesta za injiciranje so sprednji del stegen, nadlahti ali sprednji del pasu (trebuh).
The best places to inject are the front of your thighs, upper arms or the front of your waist (abdomen).
Najprimernejša mesta za injiciranje zdravila so sprednji predel stegen, nadlakti ali sprednji predel pasu (trebuh).
The best places to inject are the front of your waist (abdomen), upper arms or the front of your thighs.
Najprimernejša mesta za injiciranje so sprednji del pasu (trebuh), nadlahti ali sprednji del stegen.